Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...

According to preliminary data, the S&P 500 lost 16.58 points, or 0.28%, to end at 6,051.92 points, while the Nasdaq Composite ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

Salesforce has announced a new CFO+ with an expanded set of responsibilities as a company veteran who "bleeds CRM" prepares ...

California Democratic Rep. Jared Hoffman protested the National Prayer Breakfast Thursday, claiming it violates the separation between church and state. The congressman said in an X video […] ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

TEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims ...

(KOA), the largest system of privately owned campgrounds in the world, is proud to announce that Mt. Gilead KOA Holiday has ...

Ivanka Trump wore a timeless remake of a Givenchy dress at tonight's inauguration ball after sporting a green ensemble ahead of the inauguration which reminded some of a dystopian story ...

GS-1427 is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...